Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Pediatr Res. 2012 Oct;72(4):337-43. doi: 10.1038/pr.2012.88. Epub 2012 Jul 13.
Cardiac biomarkers are used to identify cardiac disease in term and preterm infants. This review discusses the roles of natriuretic peptides and cardiac troponins. Natriuretic peptide levels are elevated during atrial strain (atrial natriuretic peptide (ANP)) or ventricular strain (B-type natriuretic peptide (BNP)). These markers correspond well with cardiac function and can be used to identify cardiac disease. Cardiac troponins are used to assess cardiomyocyte compromise. Affected cardiomyocytes release troponin into the bloodstream, resulting in elevated levels of cardiac troponin. Cardiac biomarkers are being increasingly incorporated into clinical trials as indicators of myocardial strain. Furthermore, cardiac biomarkers can possibly be used to guide therapy and improve outcome. Natriuretic peptides and cardiac troponins are potential tools in the diagnosis and treatment of neonatal disease that is complicated by circulatory compromise. However, clear reference ranges need to be set and validation needs to be carried out in a population of interest.
心脏生物标志物用于识别足月和早产儿的心脏疾病。本文讨论了利钠肽和心脏肌钙蛋白的作用。心房应变（心房利钠肽（ANP））或心室应变（B 型利钠肽（BNP））时，利钠肽水平升高。这些标志物与心脏功能密切相关，可用于识别心脏疾病。心脏肌钙蛋白用于评估心肌细胞损伤。受影响的心肌细胞将肌钙蛋白释放到血液中，导致心脏肌钙蛋白水平升高。心脏生物标志物越来越多地被纳入临床试验，作为心肌应变的指标。此外，心脏生物标志物可能可用于指导治疗并改善预后。利钠肽和心脏肌钙蛋白是诊断和治疗因循环受损而复杂化的新生儿疾病的潜在工具。然而，需要在感兴趣的人群中设定明确的参考范围并进行验证。
